Table 1.

Incidence of mould infections and risk factors in NHL.

Authors and Notes	Moulds in NHL (%)	Moulds in iNHL (%)	Risk factors
Tisi 2017	2.3	2	neutropenia, steroid and transplant. For iNHL in particular relapse/refractory disease and salvage treatment
Teng 2015	4.3	1.7
Nosari 2014	3.2		prognostic factors: neutropenia and age
SEIFEM 2004	0.9
Takaoka 2014 NHL in salvage therapy	2.3		refractory disease, >2 lines of therapy, N<500/mmc
Sun 2015	1.26
Kurosawa 2012	0.3
Stanzani 2013 HSCT excluded	1.5		prolonged neutropenia, lymphopenia or impairment of the lymphocite compartment in HSCT, previous history of IMD and non remission disease.
Herbrecht 2012	0.8		advanced age, steroid and treatment with monoclonal antibody or purine analogs
Jantunen 2004 only autologous HSCT patients	1.9
Dimopoulos 2017 WM in ibrutinib		3.2
Wang 2015 MCL in ibrutinib		2.7
Varughese 2018 Patients in ibrutinib	3
Montagna 2012	1.4
Pagano 2017			prolonged neutropenia, disease in advanced lines of therapy and previous IFI
Pagano 2011			steroid, treatment with monoclonal antibody or purine analogs. Steroid and disseminated IFI are prognostic factors for the outcome of infection
Gil L 2009 CLD in HSCT			previous treatment with Rituximab and purine analogs
Vazques 2017			neutropenia, advanced disease, treatment with anti-CD 52, steroid and hospital near areas under costruction.
Chamilos 2018 ibrutinib			steroid, exposure to spores and number of previous lines of therapy
Fleming 2014 iNHL			previous treatment with purine analogs